Jan 13, 2023 · IMX-110 clinical trial data is expected to be released on a rolling basis beginning in Q1 2023; once dosing begins, patients undergo CT scans every 8 weeks to assess tumor response to IMX-110. “We are delighted with continued robust IMX-110 clinical trial enrollment,” said Ilya Rachman, MD PhD, CEO of ImmixBio.

Dec 20, 2022 · 16 th patient dosed with IMX-110 to date; This is the second patient dosed with IMX-110 in December 2022; Patients undergo CT scans every 8 weeks after dosing to assess tumor response to IMX-110; clinical data expected to …

Jan 19, 2022 · Our lead asset IMX-110, currently in Phase 1b/2a clinical trials, holds orphan drug designation (ODD) by the FDA for soft tissue sarcoma, and has received Rare Pediatric Disease Designation (RPDD) for the treatment of rhabdomyosarcoma, a life-threatening form of …

Feb 7, 2023 · IMX-110 + Beigene/Novartis anti-PD-1 tislelizumab combination treatment is designed to enhance response to solid tumors by turning immunologically “cold” tumors “hot”.

LOS ANGELES, Feb. 4, 2020 /PRNewswire/ -- Immix Biopharma, Inc., announced today that the first patient in the USA was dosed successfully in its flagship phase 1b /2a clinical trial testing...

Feb 7, 2023 · Immix Biopharma, Inc. today announced dosing of the first 2 patients in its IMX-110 + Beigene/Novartis anti-PD-1 Tislelizumab Combination Phase 1b/2a Clinical Trial in patients with advanced solid tumors.

Immix Biopharma announced that the first patient in the USA was dosed successfully in its flagship phase 1b/2a clinical trial testing Imx-110 in patients with refractory solid tumors. To-date, the trial has accrued patients across tumor types.

Immix Biopharma, Inc, a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases, announced patient dosing in its ongoing Phase 1b/2a IMX-110 monotherapy clinical trial. This is the fifteenth patient dosed with IMX-110 to-date.

LOS ANGELES, Feb. 07, 2023 — Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx) TM targeting oncology and immuno-dysregulated diseases, today announced dosing of the first 2 patients in its IMX-110 + Beigene/Novartis anti-PD-1 ...

Jan 13, 2023 · IMX-110 is currently being evaluated in a phase 1b/2a clinical trial in patients with advanced solid tumors. Learn more at www.immixbio.com/iMX-110 About Immix Biopharma, Inc.